Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.
Buzzoni C, et al. Among authors: randazzo m.
Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.
Eur Urol. 2015.
PMID: 25791513
Free PMC article.
Clinical Trial.
BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold increase in PCa incidence with prostate-specific antigen (PSA)-based screening (at 13 yr of follow-u …
BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cance …